Maze Therapeutics (MAZE) Tax Provisions (2024 - 2025)
Maze Therapeutics (MAZE) posted Tax Provisions of -$27.5 million for Q4 2025, down 381.89% sequentially from $9.8 million in Q4 2024, and down 381.89% YoY from $9.8 million in Q4 2024.
Maze Therapeutics (MAZE) Tax Provisions (2024 - 2025) Analysis & Trends
Maze Therapeutics has reported Tax Provisions for 2 years, with the latest figure at -$27.5 million in Q4 2025.
- Quarterly Tax Provisions fell 381.89% year-over-year to -$27.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$17.8 million (changed N/A YoY) and the FY2025 annual result came in at -$27.5 million, down 345.52% from the prior year.
- Tax Provisions fell to -$27.5 million in Q4 2025 per MAZE's latest filing, from $9.8 million in the prior quarter.
- Over five years, Tax Provisions peaked at $9.8 million in Q4 2024 and troughed at -$27.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -27.54 Mn |
| Dec 31, 2024 | 9.77 Mn |
| Sep 30, 2024 | -300,000.00 |
| Jun 30, 2024 | 1.73 Mn |